




COVID-19 Pathogenesis

Jeremy Martinson, D.Phil
Assistant Professor
Department of Infectious Diseases
and Microbiology
Graduate School of Public Health
University of Pittsburgh



Jonathan Corum & Carl Zimmer
The New York Times, April 3rd 2020

MAAETC webinar 08-06-2020



Speaker Disclosure

Speakers are required to disclose any commercial relationships before today's presentation.



Contents

- Basics of COVID-19 disease
- Appearance and spread
- Current status of the pandemic
 - Recent developments in testing, vaccines, and treatment
- Emergence from an animal reservoir
 - Likelihood of other coronavirus emergence



Kevin Olival, EcoHealth Alliance

MAAETC webinar 08-06-2020



Possible Symptoms of COVID-19

Main Common Less Common

chills nausea vomiting rash on skin
fever fatigue muscle pain
loss or change of taste or smell
shortness of breath dry cough
conjunctivitis sore throat diarrhea headache
discolouration of fingers or toes

these are not all possible symptoms - other symptoms may be possible

emergency symptoms seek medical attention

inability to wake or stay awake
difficulty breathing bluish lips or face
chest pain or pressure
loss of speech or movement new confusion

sources: US Centers for Disease Control & Prevention, World Health Organisation, UK NHS

Basics of COVID-19 disease

MAAETC webinar 08-06-2020




COVID-19 and SARS-CoV-2

- Coronavirus Disease 2019 (COVID-19) is the disease
- SARS-Coronavirus type 2 (SARS-CoV-2) is the virus that causes COVID-19
- SARS-CoV-2 is closely related to SARS-CoV, the virus that caused Severe Acute Respiratory Syndrome (SARS) in 2002
- SARS-CoV and SARS-CoV-2 are also related to MERS-CoV, the virus that causes Middle Eastern Respiratory Syndrome (MERS) in 2012/2013
- All are a type of virus called *Coronaviruses*

Coronaviruses

- Spike proteins form a crown shape (or corona) on virus surface
- Prior to SARS outbreak in 2002, coronaviruses were thought to be harmless in humans
- One of the causes of the common cold (15%)
- 3 human outbreaks
 - SARS (2002) – 8,098 cases, 774 deaths (10% CFR)
 - MERS (2013) – 2,519 cases, 866 deaths (34% CFR)
 - COVID-19 (2020) – 16.5 million cases, 650,000 deaths* (4% CFR, likely an overestimate as we do not have reliable case counts)



Science vol **339** pp1269-1273 (2013)

*as of 07/28/2020, data from Johns Hopkins University COVID-19 dashboard

The Majority of Infections are Mild

Seriousness of symptoms

80.9%



MILD

Like flu, stay at home

13.8%



SEVERE

Hospitalization

4.7%




CRITICAL

Intensive care

study of 44,672 confirmed cases in Mainland China
sources: China Center for Disease Control & Prevention

Those Aged 60+ are Most At Risk...

% of deceased (Italy & UK)



study of 3,372 death cases in UK & 21,551 deaths in Italy
sources: Italian Portal of Epidemiology for Public Health, UK Office of National Statistics




MAAETC webinar 08-06-2020

MidAtlantic AIDS Education and Training Center

Especially Those with Existing Conditions

% of deceased with *serious ailments*




study of 44,672 confirmed cases in Mainland China
sources: China Center for Disease Control & Prevention, Statista

Multiple Conditions Increase Risk

Serious conditions present in those who have died

1% no conditions



average age of victim
in this analysis was 79

having these conditions
does not mean you will
die of the disease -
they are just risk factors


Active cancer, Atrial fibrillation, Chronic Obstructive Pulmonary Disease (COPD)
Dementia, Diabetes, Heart disease, Hypertension, Liver disease (chronic),
Renal failure (chronic), Stroke

study of 355 deaths from 16,925 confirmed cases in Italy
source: Italian Portal of Epidemiology for Public Health



Biological Sex is also a Risk-Factor

% of COVID-19 deaths




source: studies of 24,922 deaths in UK & Italy

Italian Portal of Epidemiology for Public Health, UK Office of National Statistics

How Contagious & Deadly is It?

We don't fully know yet but it's in **this range**

% who die (CASE FATALITY RATE)



sources: US Centers for Disease Control & Prevention, WHO, New York Times



MAAETC webinar 08-06-2020

MidAtlantic AIDS Education and Training Center


Infection with a virus

- In the first step of infection, any virus has to recognize and interact with a specific receptor protein on the target cell's surface
- Each type of virus recognizes a different receptor
- Different cells have different proteins on their cell surface
- So, each virus can infect a specific set of cells, and not others
- SARS-CoV and SARS-CoV-2 both use the same receptor: ACE2



Infectious mechanism used by SARS-CoV-2


- ACE2 is found of pneumocytes in the lung; also enterocytes in the gut
- The spike protein of SARS-CoV and SARS-CoV-2 is cleaved by the human enzyme TMPRSS2
 - the drug [camostat mesylate](#) inhibits this
- This drug is already licensed in Europe & Japan (as a treatment for pancreatitis), and is now in a clinical trial for COVID-19



Cell vol 181 271-280.e8 (2020)


COVID-19 subversion of the immune response

- Viral infection normally induces type I interferon response in immune cells
- COVID-19 proteins block interferon α/β expression and signaling
- Viral clearance is delayed; robust B cell, T cell and cytokine response develops
- “Cytokine storm” results in lung tissue damage



Infection and disease in COVID-19


- Respiratory infection, primarily through droplets and contact with contaminated surfaces
- The extent of aerosol infection is not clear
- Many infections are mild or asymptomatic, so it is hard to determine the true case count
- Severe acute respiratory distress syndrome (ARDS) and extensive lung damage



Dr. Keith Mortman,
George Washington University

COVID-19 distinguishing features

- Spread by droplet infection (like SARS, MERS, and also influenza), **BUT**
- COVID-19 patients produce infectious virus well before they feel ill (if they feel ill at all)
 - Spreads in the general population
 - Many asymptomatic (but infectious) infections
- SARS and MERS patients only shed virus after the onset of symptoms
 - Secondary infections were most common in family members and healthcare workers




Nature (2020)
<https://doi.org/10.1038/s41586-020-2488-1>

Superspreaders in COVID-19

- Individual person who infects a large number of others
- Daegu, South Korea, Feb 2020; 70 cases linked to “patient 31” at the Shinceonji Church of Jesus
- New Rochelle NY, USA, March 2020; one person spread the virus to at least 20 individuals, creating a cluster of infections that ultimately exceeded 100
- Rheda-Wiedenbrück, Germany, March-April 2020; one asymptomatic worker at a meat packing plant infected 60% of other workers within a 25-foot radius

Prevention is better than cure



Anne Marie Darling
@amdarling

Lots of science-y folks are posting this graph. But if there is one thing I have learned from being on the internet, it is this:

Data/graphs: Not compelling to many.

Kitties: Compelling to many.

So I present: [#Catteningthecurve](#).

[#scicomm](#) [#epitwitter](#)

Source: CDC

7:16 PM · Mar 11, 2020 · [Twitter Web App](#)

26.1K Retweets 56.5K Likes

Jeremy Martinson
@jeremymartinson

Replying to @amdarling

Awesome! Here's a live re-enactment, courtesy of my two.

Jeremy Martinson
@jeremymartinson

Oreo and Spooky showing how to [#FlattenTheCurve](#) [#EpiCats](#)

7:57 AM · Mar 12, 2020 · [Tweetbot for iOS](#)

11:28 AM · Mar 12, 2020 · [Twitter Web App](#)

[View Tweet activity](#)

2 Retweets 53 Likes


MAAETC webinar 08-06-2020



Masks work

Masks reduce airborne transmission

Infectious aerosol particles can be released during breathing and speaking by asymptomatic infected individuals. No masking maximizes exposure, whereas universal masking results in the least exposure.



Science vol 368 pp1422-1424 (2020)

- SARS-CoV-2 replicates three times faster than other coronaviruses
- Can spread rapidly to the pharynx and be exhaled before the innate immune response becomes activated and the infected person shows symptoms

Coronavirus Riskiest Activities

According to 500+ epidemiologists & health professionals


📍 risk factors to consider

- 👥 **people** how many?
- 📏 **space** how close is the contact?
- 🕒 **time** how long the exposure?
- 📍 **location** inside or outside?
- 👉 **surfaces** lots of high touch?
- 📍 **area** high number of cases?
- 👤 **covidiocy** how likely is compliance?

LOW RISK



MEDIUM RISK



HIGH RISK



Risk reduced by wearing a mask, social distancing & washing hands

informationisbeautiful


sources: New York Times, Reuters, NPR, SF Gate & others

INCREASING RISK →



MAAETC webinar 08-06-2020

MidAtlantic AIDS Education and Training Center


ProMED
 INTERNATIONAL SOCIETY
 FOR INFECTIOUS DISEASES

Published Date: 2019-12-30 23:59:00
 Subject: PRO/AH/EDR> Undiagnosed pneumonia - China (HU); RFI
 Archive Number: 20191230.6864153

UNDIAGNOSED PNEUMONIA - CHINA (HUBEI); REQUEST FOR INFORMATION

A ProMED-mail post
<http://www.promedmail.org>
 ProMED-mail is a program of the
 International Society for Infectious Diseases
<http://www.isid.org>

[U]
 Date: 30 Dec 2019
 Source: Finance Sina [machine translation]
<https://finance.sina.cn/2019-12-31/detail-ihnzahk1074832.d.html?fromwap>

Wuhan unexplained pneumonia has been isolated test results will be announced [as soon as available]

On the evening of [30 Dec 2019], an "urgent notice on the treatment of pneumonia of unknown cause" was issued, which was widely distributed on the Internet by the red-headed document of the Medical Administration and Medical Administration of Wuhan Municipal Health Committee.

On the morning of [31 Dec 2019], China Business News reporter called the official hotline of Wuhan Municipal Health and Health Committee 12320 and learned that the content of the document is true.

12320 hotline staff said that what type of pneumonia of unknown cause appeared in Wuhan this time remains to be determined.

According to the above documents, according to the urgent notice from the superior, some medical institutions in Wuhan have successively appeared patients with pneumonia of unknown cause. All medical institutions should strengthen the management of outpatient and emergency departments, strictly implement the first-in-patient responsibility system, and find that patients with unknown cause of pneumonia actively adjust the power to treat them on the spot, and there should be no refusal to be pushed or pushed.

The document emphasizes that medical institutions need to strengthen multidisciplinary professional forces such as respiratory, infectious diseases, and intensive medicine in a targeted manner, open green channels, make effective connections between outpatient and emergency departments, and improve emergency plans for medical treatment.


Another piece of emergency notification, entitled "City Health and Health Commission's Report on Reporting the Treatment of Unknown Cause of Pneumonia" is also true. According to this document, according to the urgent notice from the superior, the South China Seafood Market in our city has seen patients with pneumonia of unknown cause one after another.

Current status of the pandemic

MAAETC webinar 08-06-2020




Impact of COVID-19



MAAETC webinar 08-06-2020



Infection & Fatality Rates Vary by Country




Coronavirus Infection Trajectories

Which countries are seeing the most new cases?

updated 27 Jul 2020

New cases

Avg 7-day change: <0% 0% >0% >10% Log



informationisbeautiful


code: Omid Kashan

Top nations for each stat. Sources: Johns Hopkins University, Financial Times




MAAETC webinar 08-06-2020

MidAtlantic AIDS Education and Training Center



Double-click to zoom into the map.




The New York Times, July 27th 2020

MAAETC webinar 08-06-2020




COVID-19 in Allegheny County



MAAETC webinar 08-06-2020






Recent updates in cases, treatment, and vaccines

Figure from *The New York Times*, July 20th 2020

MAAETC webinar 08-06-2020




COVID-19 detections are rising. It's not due to increased testing.



How Coronavirus Cases Compare With Expectations

The charts show how the number of reported cases compares with the expected count based on expanded testing. The gap for states with more cases than expected is highlighted. Each state is on its own scale.




The New York Times, July 24th 2020

Seroprevalence of antibodies to SARS-CoV-2 in the USA


- Convenience sample of sera collected for routine clinical testing, March – May 2020
- 16,025 samples tested
- Most had no evidence of SARS-CoV-2 antibodies
 - Proportion of reactive sera ranged from 1-7%
- But the proportion of reactive sera was much greater than the number of reported cases in each area
 - Between 6 and 24 times greater

JAMA Internal Medicine (2020)
doi:10.1001/jamainternmed.2020.4130




Coronavirus Vaccine Tracker

By Jonathan Corum, Denise Grady, Sui-Lee Wee and Carl Zimmer Updated July 27, 2020



Genetic Vaccines

Vaccines that use one or more of the coronavirus's own genes to provoke an immune response.




PHASE III

moderna **NIH** National Institutes of Health
Turning Discovery Into Health

Viral Vector Vaccines

Vaccines that use a virus to deliver coronavirus genes into cells and provoke an immune response.



PHASE II PHASE III COMBINED PHASES

AstraZeneca **UNIVERSITY OF OXFORD**

Protein-Based Vaccines

Vaccines that use a coronavirus protein or a protein fragment to provoke an immune response.




PHASE II

Z-FSW **INSTITUTE OF MEDICAL BIOLOGY**
The Biologics Company CHINESE ACADEMY OF MEDICAL SCIENCES

Whole-Virus Vaccines

Vaccines that use a weakened or inactivated version of the coronavirus to provoke an immune response.



PHASE III

武汉生物制品研究所有限责任公司
WUHAN INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD.

The New York Times, July 27th 2020

MAAETC webinar 08-06-2020




AETC AIDS Education & Training Center Program
MidAtlantic

MidAtlantic AIDS Education and Training Center

Immunity to coronaviruses after vaccination or infection

- There is no COVID-19 vaccine yet, although many are now beginning to undergo clinical trials, and COVID-19 survivors have only been infected a few months ago at most
- In the case of SARS, many infected-recovered people showed waning immunity a few years afterwards
- Responses to experimental coronavirus vaccines also decline after one year
- Will we have lifelong immunity to COVID-19?




Journal of Immunology vol 186 pp7264-7268 (2011)



Current state of COVID-19 therapies


- The antiviral drug Remdesivir shortens recovery time by 4 days on average but has no impact on mortality, compared to placebo [NEJM 2020; DOI:10.1056/NEJMoa2007764]
- The only drug shown to date to affect mortality is the steroid dexamethasone
 - Effect is greatest for patients needing oxygen, or mechanical ventilation
 - Little to no effect in less severe cases
- Other drug discovery pipelines
 - Repurposing of existing drugs [Nature 2020; doi:10.1038/s41586-020-2577-1]
 - Protein-protein interaction screening [Nature 2020; doi:10.1038/s41586-020-2286-9]

The RECOVERY study: impact of dexamethasone on mortality



“Scientifically robust and ethically sound clinical research remains the quickest and most efficient pathway to effective treatment and prevention strategies for patients with Covid-19”

-accompanying editorial by Lane & Fauci




New England Journal of Medicine advance publication
DOI: 10.1056/NEJMoa2021436

MAAETC webinar 08-06-2020




Are there any human genes that affect COVID-19 severity?



New England Journal of Medicine, advance publication
DOI: 10.1056/NEJMoa2020283

MAAETC webinar 08-06-2020





Where did SARS-CoV-2 come from, and are there others?


Nature vol **583** pp366-368 (2020)

MAAETC webinar 08-06-2020



Multiple early introductions of COVID-19 into the USA from China

- USA
- China



MAAETC webinar 08-06-2020




Washington state and California cases

- Washington
- California

CA2

WA1




MAAETC webinar 08-06-2020



Later introductions from Europe


- New York
- Europe



MAAETC webinar 08-06-2020



How do coronaviruses infect humans?



Trends in Microbiology vol 25 pp35-48 (2017)

MAAETC webinar 08-06-2020



Zoonotic transfer of coronavirus in SARS

Horseshoe bat



Coronavirus 88-92% similarity to human

Palm civet



Coronavirus 99.8% similarity to human


Wet market




After the initial zoonotic transfer to humans, almost all infections were due to human-to-human spread

MAAETC webinar 08-06-2020

Zoonotic transfer of coronavirus in MERS



Lancet Infectious Diseases
vol 15 pp495-497 (2015)




Lancet vol 386 pp995-1007 (2015)

MAAETC webinar 08-06-2020



Zoonotic transfer of coronavirus in COVID-19?



MAAETC webinar 08-06-2020



The Huanan Seafood and Wildlife Market in Wuhan, China




Cell vol 181, pp223-227 (2020)

MAAETC webinar 08-06-2020



Coronavirus adaptation to humans

- The interaction between the spike protein, especially the receptor-binding domain (RBD) with ACE2, is critical to infection
- Early in the SARS outbreak, the SARS-CoV RBD underwent two small genetic changes that increased its binding affinity for human ACE2 by 1,000 fold
- This allowed for extensive human-to-human transmission after the initial species jump
- Similar small changes seen in MERS



Nature Microbiology vol 5 pp562-569 (2020)

How are SARS-CoV and SARS-CoV-2 different?

```

*****
BatRaTG13  CLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSECDIPIGAGICASYQTQNS-----KSVASQSIIAYTMSLGAENSVAYSNNNSIAIPTNFTTISVTTTEILPVSMTKTSVDCTMYTCG
Wuhan      CLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSECDIPIGAGICASYQTQNSPRRARSVASQSIIAYTMSLGAENSVAYSNNNSIAIPTNFTTISVTTTEILPVSMTKTSVDCTMYTCG
    
```

- Both use ACE2 as an entry receptor, but the course of disease is very different
- SARS case fatality rate was 10%; COVID-19 is much lower (1-2% current estimate)
- COVID-19 patients have virus in the upper respiratory tract; SARS patients did not
- ACE2 levels are lower on cells of the upper respiratory tract
- SARS-CoV-2 spike protein has an extra region that SARS-CoV does not. This **polybasic furin-type cleavage site** increases fusion activity and may allow the virus to enter cells with lower levels of ACE2

```

Wuhan 23481 CTAATGTTTTTCAAAACAGTGCAGGCTGTTTAAATAGGGGCTGAACATGTCAACCACTCAT 23540
RaTG13 23463 CTAATGTTTTTCAAAACAGTGCAGGCTGTTTAAATAGGGGCTGAACATGTCAATAACTCGT 23522

Wuhan 23541 ATGAGTGTGACATACCCATTGGTGCAGGTATATGCGCTAGTTATCAGACTCAGACTAATT 23600
RaTG13 23523 ATGAGTGTGACATACCTATTGGTGCAGGAATATGCGCCAGTTATCAGACTCAAACAAATT 23582

Wuhan 23601 CTCTCGGGCGGCAGTGTAGTGTAGTCAATCCATCATTGCCTACACTATGTCACTTG 23660
RaTG13 23583 -----CACGTAGTGTGGCCAGTCAATCTATTATTGCCTACACTATGTCACTTG 23630

Wuhan 23661 GTGCAGAAAATTTCAGTTGCTTACTCTAATAACTCTATTGCCATACCCACAATTTTACTA 23720
RaTG13 23631 GTGCAGAAAATTTCAGTTGCTTATTCTAATAACTCTATTGCCATACCTACAATTTTACTA 23690

Wuhan 23721 TTAGTGTACCACAGAAAATTCACCAGTGTCTATGACCAAGACATCAGTAGATTGTACAA 23780
RaTG13 23691 TTAGTGTGACCACATGAAATTCACCTGTGTCATGACCAAGACATCGGTAGACTGTACAA 23750
    
```


...but it's not an engineered virus (unless they did it really badly)

<http://virological.org/t/tackling-rumors-of-a-suspicious-origin-of-ncov2019>

MAAETC webinar 08-06-2020





SARS-CoV-2 is mutating like other coronaviruses



MAAETC webinar 08-06-2020



Is COVID-19 evolving to become more deadly?




The New York Times, June 12th 2020

MAAETC webinar 08-06-2020



Why do bats carry so many viruses that are fatal to humans?

- SARS, MERS, COVID-19, Nipah, Hendra, Ebola, Marburg, *etc*
- Bats roost together in large numbers, often with members of other species
- Bats harbor these viruses but do not get sick and die – how?
 - Bats have evolved a complex series of immune responses that enable them to tolerate the presence of many viruses
- Bats are flying mammals and have a high body temperature
 - viruses that can survive this can survive the high fever in humans that is intended to kill pathogens



Cell vol 173 pp1098-1110 (2018)

Will COVID-19 be the last new coronavirus infection?

- There are many Coronaviruses circulating in many bat species
- 6.5% of bats surveyed harbor one or more coronaviruses (Tang et al (2006), J. Virol vol 80 pp7481-7490)
- EcoHealth Alliance data: \approx 400 novel coronaviruses in bats in China; multiple “spillover” events where these have infected humans, but not spread



Viruses vol 11, 210 (2019)
Each red block represents one CoV in one bat species

The global virome project

- Around 263 viruses from 25 viral families are currently known to infect humans
- Estimated that ~1.67 million yet-to-be-discovered viral species from key zoonotic viral families exist in mammal and bird hosts
- Reasonable expectation is that between 631,000 and 827,000 of these unknown viruses have zoonotic potential
- GVP launched in 2018, with goal of identifying this viral threat

Science vol **359** pp872-874 (2018)

GVP targeting strategy

The project will capitalize on economies of scale in viral testing, systematically sampling mammals and birds to identify currently unknown, potentially zoonotic viruses that they carry.



111 viral families have been discovered globally to date.



Of these 111 viral families, the GVP will target **25** containing viruses known to infect (or to have substantial risk of infecting) people.



In these 25 families, an estimated **1.67 million** unknown viruses exist in mammals and birds—hosts that represent 99% of the risk for viral emergence.



Of these 1.67 million viruses, an estimated **631,000 to 827,000** likely have the capacity to infect people.



Summary

- COVID-19 is a severe disease caused by infection with SARS-CoV-2
- Coronaviruses are a widespread family of viruses that typically do not cause severe disease
- SARS-CoV-2 infects cells after its spike protein interacts with ACE2
 - mutations in the spike protein facilitate infection in humans
- The long-term immune response to COVID-19 is unknown
- There are MANY more coronaviruses out there

MidAtlantic AIDS Education and Training Center - Contact Information

Headquarters:

MidAtlantic AIDS Education and Training Center
Department of Infectious Diseases and Microbiology,
Graduate School of Public Health,
University of Pittsburgh

412-624-1895

maaetc@pitt.edu

www.maaetc.org

Linda Rose Frank, PHD, MSN, ACRN, FAAN
Principal Investigator and Program Director
Professor of Public Health, Medicine & Nursing
University of Pittsburgh

